Navigation Links
Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
Date:6/7/2009

LONDON, RESEARCH TRIANGLE PARK, N.C., and NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.

In the study, dose-dependent reductions in A1C - a measure of how well blood sugar is being controlled over time - with albiglutide 30 mg weekly, 50 mg biweekly, and 100 mg monthly were 0.9%, 0.8% and 0.9% respectively (p<0.05). The A1C reduction by placebo was 0.2% and by open-label exenatide was 0.5%. Weight loss (0.9 to 1.8 kg) was observed across all doses. The most frequently reported adverse events included nausea, vomiting and headache. At the 30 mg weekly dose, fewer than 10% of patients experienced nausea and vomiting, which subsided after week eight. Albiglutide was not shown to increase the risk of abnormally low blood sugar, known as hypoglycemia.

"Despite a range of available diabetes therapies, over half of patients with type 2 diabetes are unable to achieve the ADA target blood sugar goal," said the study's lead investigator, Julio Rosenstock, MD of the Dallas Diabetes and Endocrine Center at Medical City and clinical professor of medicine, University of Texas Southwestern Medical School. "While these results need to be confirmed in ongoing studies, the findings with albiglutide are important since weight gain and fear of increased blood sugar levels can be major barriers to diabetes management."

Study design

The primary objective of the study was to evaluate the dose response of albiglutide for safety and efficacy. The primary efficacy endpoint was cha
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , August 27, 2014 ... Equipment Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental ... published by MarketsandMarkets, the global Dental Equipment Market is ... $5,416.3 million in 2014, growing at a CAGR ... Browse 95 market data tables and 61 figures ...
(Date:8/27/2014)... , Aug. 27, 2014 Pulse Systems, ... (EHR) , Practice Management , and Revenue Cycle ... known business practices performed by some RCM vendors, at UBM ... PA on September 19-20, 2014.  ... will return in September with a new session encouraging practices ...
(Date:8/27/2014)... HONG KONG , Aug. 27, 2014 /PRNewswire/ ... ("Sihuan Pharmaceutical" or the "Company"), a leading pharmaceutical ... franchise in China,s prescription ... of the Company and its subsidiaries (collectively the ... 2014 (the "Period"). Financial HighlightsFor the ...
Breaking Medicine Technology:Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 2Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 4Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
... (Nasdaq: STXS ) announced today financial results for ... with the preliminary results reported on October 13, 2010. Third ... and reductions in both operating loss and net loss. ... compared to $13.3 million in the third quarter 2009. As ...
... Quality Forum (NQF) announces the election of leadership ... NQF is a unique, multi-stakeholder, nonprofit ... healthcare by setting national priorities and goals for ... and publicly reporting on performance, and promoting the ...
Cached Medicine Technology:Stereotaxis Reports Third Quarter Financial Results 2Stereotaxis Reports Third Quarter Financial Results 3Stereotaxis Reports Third Quarter Financial Results 4Stereotaxis Reports Third Quarter Financial Results 5Stereotaxis Reports Third Quarter Financial Results 6Stereotaxis Reports Third Quarter Financial Results 7National Quality Forum Members Elect New Council Leaders 2
(Date:8/27/2014)... Aug. 26, 2014 (HealthDay News) -- Health care workers ... gear to keep them safe from being infected with ... study shows. While the study was conducted before ... spring, its findings are confirmed in statistics released Monday ... health agency reported that an "unprecedented" number of health ...
(Date:8/27/2014)... and a new UCLA study has shown this is definitely ... decisions about how to treat their prostate cancer. , UCLA ... disease have a much more difficult time making treatment decisions, ... quality of their care and their long-term outcomes. , The ... can use the findings to target men less likely to ...
(Date:8/27/2014)... CIC microGUNE, the Co-operative Research Centre into ... seeks to generate innovative solutions based on ... mobility industry and life sciences, among others. ... Tecnun are collaborating with CIC microGUNE on ... funded by the Etortek 2013-2014 programme of ...
(Date:8/27/2014)... a week of tomatoes have an 18 per cent ... , With 35,000 new cases every year in the ... second most common cancer in men worldwide. , Rates ... is linked to a Westernised diet and lifestyle. , ... risk of prostate cancer, researchers at the Universities of ...
(Date:8/27/2014)... news release is available in German . ... for medical agents to treat metastatic tumors. In case of ... that is often detected late, 95% of the patients die ... develops tumor therapeutic agents that might reduce this mortality rate. ... now received a total of EUR 5 million from investors. ...
Breaking Medicine News(10 mins):Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 2Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 3Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Fighting prostate cancer with a tomato-rich diet 2Health News:Preclinical development of tumor therapeutic agent starts 2
... VP of Products and Marketing Will Address Growing Healthcare Trends ... Tools ... Michael Flanagan, VP of products,and marketing for Portico Systems, the ... Optimizing Provider,Network Management" at the Institute for International Research,s,conference in ...
... Barcelona, Spain: Recent political decisions have had serious ... at ECCO 14, the European Cancer Conference, today ... the Federation of European Cancer Societies (FECS) said ... take an active role in engaging with policymakers ...
... spontaneous quit attempts can be successful, PITTSBURGH, ... quit attempt may not be the path to ... for a quit attempt, a new national,survey conducted ... quitting may not require an advance plan.(1) In ...
... of Diabetic Neuropathy Market Will Be Driven by Launches, of ... ... Resources, WALTHAM, Mass., Sept. ... firms for pharmaceutical and,healthcare issues, finds that by 2016 Genentech/Roche,s Lucentis ...
... the Cure with its ... Emmy Award-winning journalist and TV personality Cristina ... Munchkin, Inc. -- maker of award-winning infant and ... again reminding women everywhere "Don,t Duck a ...
... to encourage an individual to get screened for ... according to researchers at Jefferson Medical College in ... interventions that guide recipients through the screening process ... primary care practices. , Ronald Myers, Ph.D., professor ...
Cached Medicine News:Health News:Portico Systems to Share Provider Network Management Best Practices at Institute for International Research 2Health News:Political decisions harming cancer treatment in Europe 2Health News:Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning 2Health News:Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning 3Health News:Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning 4Health News:Genentech/Roche's Lucentis and Eli Lilly's Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets 2Health News:Cristina Saralegui Joins Celebrities Including Matthew McConaughey, Courteney Cox and Mariska Hargitay to Raise Money for Breast Cancer Research 2Health News:Jefferson researchers find personalized interventions key to improving colon cancer screening rates 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: